(Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine is under clinical development by Serum Institute of India and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect (Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine’s likelihood of approval (LoA) and phase transition for Meningitis took place on 28 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
(Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine overview
Vaccine candidate is under development for the prevention of meningitis. The vaccine candidate is a pentavalent meningococcal conjugate vaccine (A, C, Y, W-135, X). It is administered by intramuscular route. The vaccine comprises of MenX capsular polysaccharide (PS) that is conjugated to tetanus toxoid, it is also formulated as thermostable.
Serum Institute of India overview
Serum Institute of India (Serum Institute), a subsidiary of Cyrus Poonawalla Group, is a biotechnology company that manufactures and supplies vaccines and immuno-biologicals to treat polio, diphtheria, tetanus, pertussis, r-hepatitis B, measles, mumps and rubella. The company’s product portfolio includes bacterial, viral, covid, influenza, polysaccharide conjugate and combination vaccines; recombinant and pharma products; and anti-sera vaccines. It markets the Oxford–AstraZeneca COVID-19 vaccine under the brand name Covishield in India. It is investigating DTaP, an acellular vaccine against pertussis; pentavalent meningococcal conjugate vaccine to prevent epidemic group A meningococcal disease; ErepoXen, to maintain red blood cell production and prevent anemia caused by chronic kidney failure; and HPV vaccine against cervical cancer. Serum Institute is headquartered in Pune, Maharashtra, India
Quick View (Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine LOA Data
|Highest Development Stage|